Mercado de imagens de ensaios clínicos da América do Norte – Tendências do setor e previsão para 2029

Análise e insights do mercado de imagens de ensaios clínicos da América do Norte

A crescente procura de tecnologia de imagem, seguida pelo aumento da prevalência de doenças crónicas devido ao aumento da população idosa e às iniciativas estratégicas dos participantes do mercado, como o lançamento de produtos, o avanço, a aquisição e os acordos, são os factores que deverão impulsionar o crescimento do mercado.

No entanto, espera-se que cenários de reembolso inadequados e desfavoráveis ​​para dispositivos de imagem e a falta de padrões bem definidos nos instrumentos de imagem de ensaios clínicos restrinjam o crescimento do mercado.

Espera-se que as crescentes progressões tecnológicas na imagiologia de ensaios clínicos para o diagnóstico e tratamento de doenças crónicas impulsionem o crescimento do mercado. A Data Bridge Market Research analisa que o mercado norte-americano de imagiologia de ensaios clínicos crescerá a um CAGR de 8,3% durante o período de previsão de 2022 a 2029.

Definição de mercado

O ensaio clínico é um processo de desenvolvimento de novos medicamentos. Foi concebido para o tratamento potencial e os seus efeitos em humanos. Antes da comercialização de novos medicamentos, são feitos extensos testes clínicos para identificar compostos promissores e testes de segurança para determinar os possíveis riscos.

In clinical trials, medical imaging plays a significant role in more accurate and effective results. Different imaging technologies may be used to elucidate and demonstrate the mechanistic actions of drugs. Clinical trial imaging is the process of clinical analysis and medical intervention by creating image representations of inner parts of the body. It has several different technologies which are used to view the human body to monitor, treat, and diagnose medical conditions.

In the coming future, important decisions related to clinical trial imaging on drug discovery will be made by individuals who not only understand the biopsy but can also use the clinical trial imaging tools and the knowledge they release to develop hypotheses and identify quality targets.

North America Clinical Trial Imaging Market Dynamics

Drivers

• Rising R&D Expenditure

Imaging and pharma companies are continuously investing in R&D to offer innovative services for clinical trial imaging to customers and enhance their market presence. Medical imaging plays a dynamic role in clinical development. While the medical imaging industry is in a constant state of fluctuation due to implementation of new technologies in the market, the pharmaceutical and imaging industries continue to increase. This is attributed to enhanced investment in medical imaging companies along with mergers and acquisitions as well as the adoption of innovation in imaging technologies to support clinical trials for medical devices. Increasing R&D expenditure in pharmaceutical and biotechnological companies is fueling market growth.

This has encouraged the development of new products and high research-oriented programs organized in biopharmaceutical industries and a high preference for the studies of human genome. Rising expenditure on R&D activities also develops new drugs and therapies to treat chronic diseases that boost market growth. This helps the pharmaceutical and biotechnological companies in the development of new technologies in the category of imaging clinical trials therefore, rising R&D expenditure is expected to drive the market growth.

• Increasing Number of Contract Research Organizations (CROs)

Contract Research Organization (CRO) is an organization that gives support for clinical trials and other research services to imaging and pharmaceutical industries in the form of outsourced pharmaceutical research services in terms of both drugs and medical devices. CRO helps imaging and pharmaceutical industries with the drug development process to reduce the cost and initiate the process of bringing clinical trials to develop the drug for a particular disease segment by using clinical trial imaging and other processes to overcome capacity gaps of the in-house research team for pharmaceutical and clinical research.

CRO is the backbone of the clinical trial industry. CROs manage all aspects of a clinical trial. In the clinical trial services, CRO offers various drug development services, such as:

A huge number of CROs are engaged in monitoring the drug development process such as PAREXEL (U.S.), PRA Health Sciences (U.S.), Labcorp (U.S.), PPD (U.S.), Syneos Health (U.S.), ICON plc (Ireland), Envigo (U.K.), Charles River (U.S.), and SGS (Switzerland) among others. These are some CROs that are engaged to give support for clinical trials and other research services to the imaging and pharmaceutical industries. The increasing number of CROs is expected to drive market growth.

Opportunities

• Rise in Healthcare Expenditure

Healthcare expenditure has increased across the world as people's disposable income in various countries is increasing. Moreover, to accomplish the population requirements, government bodies and healthcare organizations are taking the initiative by virtue of accelerating healthcare expenditure.

Growing healthcare expenditure is also beneficial for further growth in economic and healthcare sector, and it is primarily fruitful as it significantly affects the development of better and advanced medical products in the market. Therefore, the surge in healthcare expenditure is expected to create a greater opportunity for the market.

• Strategic Initiatives by Market Players

The demand for clinical trial imaging is increasing in the market owing to the increased levels of R&D along with the growth of clinical trial imaging market aided by the desire for innovative medications. Thus, the top market players have implemented a new strategy by developing new products and collaborating with other market players to improve business operations and profitability.

For instance,

• In June 2022, Parexel, a leading global CRO, announced the launch of its Community Alliance Network, a novel program further integrating clinical research into the community healthcare setting to better serve patients and in turn create further opportunities for increased diversity in clinical trials. CVS Health, the leading health care solutions company, and Javara, the leading Integrated Research Organization, have joined the network as inaugural members, opening the door to community-based research sites and increasing access to new patient populations to support trial delivery for Parexel’s biopharmaceutical customers.
• In February 2020, ICON plc acquired MedPass International, a European medical devices CRO, reimbursement, and regulatory consultancy. This acquisition has reportedly helped in the expansion of the medical device and diagnostic research services of ICON in Europe.

These strategic initiatives by the market players, including acquisition, conferences, and focused segment product launches, are helping them grow and improve the company's product portfolio, ultimately leading to more revenue generation. Hence, these strategic initiatives by the market players may act as an opportunity for market growth.

Restraints/Challenges

• High-Risk Radiation Causing Diseases

In clinical medical imaging, radiation is absorbed by the body which can harm the molecular structures inside the patient’s body. High doses of radiation can affect human cells including loss of hair, skin burns, and increased incidence of cancer. The estimated risk of developing fatal cancer is one in 2000 after going through a radiation dose of 10 mSv in a CT scan.

For instance,

• According to Radiological Society of North America (RSNA), 1% to 2% of all cancers in the U.S. are caused by CT scans and the American Cancer Society identified CT scans and X-rays as one of the reasons for breast cancer, brain cancer, and other cancers
• According to Center for Disease Control and Prevention, exposure to high levels of radiation results in acute radiation syndrome. The amount of radiation that a person's body absorbs is called the radiation dose.

The high-risk radiation that occurs, would decrease the usage and sale of clinical trial imaging devices, thereby affecting the credibility of manufacturers involved in this market. Therefore, the high-risk radiation-causing diseases are expected to restrain the market growth.

• Strict Regulatory Policies

The healthcare industry is regulated by a structure of laws, and rules & regulations that are extensive and complex.

For instance,

• In April 2018, the U.S. FDA released updated Guidance for Clinical Trial Imaging Endpoint Process Standards for the industry which includes the quality of imaging data obtained in clinical trials
• Biotechnology and pharmaceutical industries need to take first approval from the FDA for the process of drug development. They have to submit an Investigational New Drug (IND) application to the FDA before beginning clinical research.

COVID-19 Impact on the North America Clinical Trial Imaging Market

Diagnostic imaging services have been time-consuming and complicated by the need for strict infection control and prevention practices developed to contain the risk of transmission and protect healthcare personnel. Hence, the decision to image suspected patients or COVID-19-positive patients is based on their impact on the improvement of patient status. The American College of Radiology (ACR), does not recommend Computed Tomography (CT) as a first-line diagnostic test for COVID-19 patients and limits computed tomography utility to symptomatic and hospitalized patients with specific clinical indications.

Recent Developments

• Em janeiro de 2022, a Clario estabeleceu uma parceria com a XingImaging, uma empresa de produção de radiofármacos e aquisição de tomografia por emissão de positrões (PET), para realizar ensaios clínicos de imagiologia PET para testar novas terapêuticas na China. A parceria oferece a partilha de recursos conjuntos e especialistas em neurociências da Clario e da XingImaging para acelerar o início de ensaios clínicos e descoberta de medicamentos na China.
• Em novembro de 2021, foi constituída a Clario. A ERT e a Bioclínica fundiram-se para formar a Clario. A formação da nova empresa resultou na distribuição de software e serviços de imagiologia clínica e no aumento das vendas.

Âmbito do mercado de imagens de ensaios clínicos da América do Norte

O mercado norte-americano de imagiologia de ensaios clínicos está segmentado em cinco segmentos com base nos produtos e serviços, modalidade, aplicação, utilizador final e distribuidor. O crescimento entre estes segmentos irá ajudá-lo a analisar segmentos de crescimento escasso nas indústrias e fornecer aos utilizadores uma valiosa visão geral do mercado e insights de mercado para os ajudar a tomar decisões estratégicas para identificar as principais aplicações do mercado.

Produtos e Serviços

• Serviços
• Software

Com base nos produtos e serviços, o mercado está segmentado em serviços e software.

Modalidade

• Tomografia Computadorizada
• Imagem por ressonância magnética
• Ecocardiografia
• Medicina Nuclear
• Tomografia por emissão de positrões
• raio X
• Ultrassom
• Tomografia de Coerência Óptica
• Outros

Com base na modalidade, o mercado está segmentado em tomografia computorizada , ressonância magnética , ecocardiografia, medicina nuclear, tomografia por emissão de positrões, raio X, ecografia, tomografia de coerência óptica e outros.

Aplicação

• Oncologia
•  Neurologia
•  Cardiologia
•  Endocrinologia
•  Dermatologia
•  Hematologia
•  Outros

Com base na aplicação, o mercado está segmentado em oncologia , neurologia, cardiologia, endocrinologia, dermatologia, hematologia e outras.

Utilizador final

• Organizações de investigação contratada
• Empresas farmacêuticas e de biotecnologia
• Fabricantes de dispositivos médicos
• Institutos de Investigação Académica e Governamental
• Outros

Com base no utilizador final, o mercado está segmentado em organizações de investigação por contrato , empresas farmacêuticas e de biotecnologia, fabricantes de dispositivos médicos, institutos de investigação académicos e governamentais e outros.

Distribuidor

• Vendas Diretas
•  Vendas de propostas

Com base no distribuidor, o mercado está segmentado em vendas diretas e vendas por concurso.

Análise/perspetivas regionais do mercado de imagiologia de ensaios clínicos da América do Norte

O mercado norte-americano de imagiologia de ensaios clínicos é analisado, e são fornecidos insights e tendências de tamanho de mercado por regiões, produtos e serviços, modalidade, aplicação, utilizador final e distribuidor, conforme mencionado acima.

Os países abordados neste relatório de mercado são os EUA, o Canadá e o México. Espera-se que os EUA dominem o mercado devido ao aumento da incidência de cancro, à procura de imagiologia médica não invasiva, ao crescimento das inovações tecnológicas em imagiologia de ensaios clínicos e ao aumento das atividades de I&D.

A secção do país do relatório também fornece fatores individuais que impactam o mercado e alterações nas regulamentações do mercado interno que impactam as tendências atuais e futuras do mercado. Pontos de dados como novas vendas, vendas de reposição, demografia do país, epidemiologia de doenças e tarifas de importação e exportação são alguns dos principais indicadores utilizados para prever o cenário de mercado para países individuais. Além disso, são considerados a presença e a disponibilidade das marcas norte-americanas e os desafios enfrentados devido à concorrência grande ou escassa do impacto das marcas locais e nacionais nos canais de vendas, ao mesmo tempo que se fornece uma análise de previsão dos dados do país.

Análise do cenário competitivo e da quota de mercado de imagens de ensaios clínicos da América do Norte

O panorama competitivo do mercado norte-americano de imagiologia de ensaios clínicos fornece detalhes sobre o concorrente. Os detalhes incluídos são a visão geral da empresa, finanças da empresa, receitas geradas, potencial de mercado, investimento em I&D, novas iniciativas de mercado, presença na América do Norte, localizações e instalações de produção, capacidades de produção, pontos fortes e fracos da empresa, lançamento de produto, largura e amplitude do produto, e domínio de aplicação. Os dados acima fornecidos estão apenas relacionados com o foco das empresas relacionado com o mercado norte-americano de imagiologia de ensaios clínicos.

Alguns dos principais players que operam no mercado são a Navitas Life Sciences, Resonance Health Analytical Services, BioTelemetry, a Philips Company, ICON plc, Quotient Sciences, WORLDCARE CLINICAL, Clario, Paraxel International Corporation, Median Technologies, Perspectum, Calyx, WIRB-Copernicus Group e Invicro.LLC, entre outros.

SKU-47941